Abbott Laboratories (ABT) is a Healthcare stock trading at $100.66 (as of 2026-07-17), with a market capitalization of $175.32B and a trailing P/E of 27.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its product offerings include pharmaceutical therapies, diagnostic laboratory and molecular systems, point-of-care testing, and nutritional and medical device products for health care customers.
Abbott Laboratories discovers, develops, manufactures, and sells healthcare products worldwide, earning revenue across four reported areas (Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices).
Because Abbott operates across four healthcare segments, its profit depends on demand and performance across multiple product categories (not just one platform).
Business quality (Mixed): Segment-level revenue detail is not cleanly available from the provided facts for all four reportable segments (notably Medical Devices), so a mutually exclusive segment revenue table cannot be constructed without gaps or double counting.
Valuation: At 25× earnings, ABT trades 47% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $100.66 |
| Market Cap | $175.32B |
| P/E Ratio | 27.9 |
| EV / EBITDA | 22.1 |
| Price / Book | 3.33 |
| Price / Sales | 3.88 |
| FCF Yield | 4.2% |
| DCF Value (model) | $47.89 |
| DCF Upside vs Price | -52.4% |
| Revenue (TTM) | $44.33B |
| Net Margin | 14.7% |
| Revenue Growth (YoY) | 7.8% |
| EPS Growth (YoY) | -18.4% |
| FCF Growth (YoY) | -1.8% |
| Altman Z-Score | 4.84 (safe) |
| Piotroski F-Score | 5/9 (moderate) |
| Stock P/E | 27.9 |
| Sector P/E (Healthcare) | 21.4 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | 30.3% |
| vs Industry | 64.6% |
| Insider Buys (12mo) | 3 |
| Insider Sells (12mo) | 2 |
| Top Institutional Holder | VANGUARD GROUP INC ($22.00B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Robert Ford |
| Employees | 114,000 |
| Country | US |
| IPO Date | 1994-03-03 |
Data as of 2026-07-17.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.